Patients with chronic spontaneous urticaria who used ligelizumab reported significant improvements in their sleep quality as compared to patients who received omalizumab or placebo, demonstrated a recent study. The clinical research by a team of doctors led by Dr Ana Giménez-Arnau, a Professor of Dermatology at Universitat Autònoma in Barcelona, and published in Clinical and Translational Allergy, indicated that the participants of their study showed sustained improvements in their sleep interference scores from baseline for the full 52-week treatment period, with a gradual increase in Weekly Sleep Interference Scores (SIS7) scores. The researchers highlighted the importance of their findings and called for further phase 3 studies on its effects on sleep as well as considering sleep quality in integrated treatment approaches.